ArticleToxins2012
In vitro antiplasmodial activity of phospholipases A2 and a phospholipase homologue isolated from the venom of the snake Bothrops asper.
Article in Toxins, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Pooled it
- Brief history of ophidiology and ophidism in Colombia.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2026Review
- The recombinant protein of scorpion venom phospholipase A2 exhibits potential anti-leishmanial activity.Scientific reports · 2025Article
- Biomedical and Biotechnological Potential of Animal Venoms:Current medicinal chemistry · 2025Review
- Toxins from Animal Venoms as a Potential Source of Antimalarials: A Comprehensive Review.Toxins · 2023Review
- The Potassium Channel Blocker β-Bungarotoxin from the KraitBiomedicines · 2023Article
- Past, Present, and Future of Naturally Occurring Antimicrobials Related to Snake Venoms.Animals : an open access journal from MDPI · 2023Review
- Antiprotozoal Effect of Snake Venoms and Their Fractions: A Systematic Review.Pathogens (Basel, Switzerland) · 2021Review
- The Metabolomic Profiles of Sera of Mice Infected with Plasmodium berghei and Treated by Effective Fraction of Naja naja oxiana UsingActa parasitologica · 2021Article
- Antimalarial activity of basic phospholipases AToxicon: X · 2020Article
- Analysis of the active fraction of IranianIranian journal of basic medical sciences · 2020Article
- Review
- Anticancer Activity of Toxins from Bee and Snake Venom-An Overview on Ovarian Cancer.Molecules (Basel, Switzerland) · 2018Review
- Article
- Antitumoral activity of snake venom proteins: new trends in cancer therapy.BioMed research international · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The antimicrobial and antiparasite activity of phospholipase A(2) (PLA(2)) from snakes and bees has been extensively explored. We studied the antiplasmodial effect of the whole venom of the snake Bothrops asper and of two fractions purified by ion-exchange chromatography: one containing catalytically-active phospholipases A(2) (PLA(2)) (fraction V) and another containing a PLA(2) homologue devoid of enzymatic activity (fraction VI). The antiplasmodial effect was assessed on in vitro cultures of Plasmodium falciparum. The whole venom of B. asper, as well as its fractions V and VI, were active against the parasite at 0.13 ± 0.01 µg/mL, 1.42 ± 0.56 µg/mL and 22.89 ± 1.22 µg/mL, respectively. Differences in the cytotoxic activity on peripheral blood mononuclear cells between the whole venom and fractions V and VI were observed, fraction V showing higher toxicity than total venom and fraction VI. Regarding toxicity in mice, the whole venom showed the highest lethal effect in comparison to fractions V and VI. These results suggest that B. asper PLA(2) and its homologue have antiplasmodial potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.